The vascular endothelial growth factor (VEGF) and its receptors have been implicated as key-factors in tumor angiogenesis and are major targets in cancer therapy. New oligomers which mimic the architecture of DNA-binding polyamides have been designed to target the hypoxia inducible factor (HIF-1α) binding site on the promoter of VEGF gene. These oligomers incorporate an increasing number of six–five fused rings such as ...
